Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome.
Department of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
C M
CM
Harper
A G
AG
Engel
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D006801:Humans; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D017354:Point Mutation; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use*; D011950:Receptors, Cholinergic / Q000235:genetics*; D013577:Syndrome
D011950:Receptors, Cholinergic; D011802:Quinidine